OBIO

MKT CAP:$244M

Orchestra BioMed Holdings, Inc.

Market Cap

$244M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$4.15-$0.16 (-3.71%)

Apr 23, 2026

Company Details

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfus...

CEO

David Hochman

IPO Date

Aug 4, 2020

Website

orchestrabiomed.com

Key Metrics TTM

Revenue

$33M

+1169.2% YoY

Net Income

-$53M

EPS (Diluted)

-$1.28

Free Cash Flow

-$49M

Revenue / Share

$0.87

Gross Margin

99.4%

Operating Margin

-154.7%

Net Margin

-157.4%

FCF Margin

-147.7%

P/S

7.3x

P/E

—

Earnings Reports

Q1 2026

May 11, 2026

PENDING

FY 2025

Mar 12, 2026

$33M+1169.2%EPS -$1.11

Q4 2025

Mar 12, 2026

$31M+12120.2%EPS $0.11

Q3 2025

Nov 10, 2025

$861.0K-12.8%EPS -$0.40

Q2 2025

Aug 12, 2025

$836.0K+7.5%EPS -$0.50

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$866.0K	$824.0K	-$5M
Q2 22	$401.0K	$341.0K	-$8M
Q3 22	$1M	$1M	-$10M
Q4 22	$1M	$1M	-$10M
Q1 23	$1M	$1M	-$12M
Q2 23	$915.0K	$861.0K	-$13M
Q3 23	$419.0K	$378.0K	-$15M
Q4 23	$262.0K	$179.0K	-$12M
Q1 24	$620.0K	$512.0K	-$14M
Q2 24	$778.0K	$734.0K	-$17M
Q3 24	$987.0K	$919.0K	-$16M
Q4 24	$253.0K	$195.0K	-$17M
Q1 25	$868.0K	$824.0K	-$19M
Q2 25	$836.0K	$790.0K	-$19M
Q3 25	$861.0K	$812.0K	-$20M
Q4 25	$31M	$31M	$7M

Valuation

Quarter	P/S	P/E
Q1 22	—	—
Q2 22	2142.0x	—
Q3 22	—	—
Q4 22	78.8x	—
Q1 23	167.1x	—
Q2 23	53.6x	—
Q3 23	85.6x	—
Q4 23	105.8x	—
Q1 24	80.0x	—
Q2 24	128.8x	—
Q3 24	71.5x	—
Q4 24	59.3x	—
Q1 25	54.6x	—
Q2 25	34.8x	—
Q3 25	33.5x	—
Q4 25	4.8x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$5M	-$5M
Q2 22	-$9M	-$9M
Q3 22	-$5M	-$5M
Q4 22	-$9M	-$9M
Q1 23	-$14M	-$14M
Q2 23	-$10M	-$11M
Q3 23	-$10M	-$10M
Q4 23	-$11M	-$11M
Q1 24	-$13M	-$13M
Q2 24	-$10M	-$10M
Q3 24	-$14M	-$14M
Q4 24	-$14M	-$14M
Q1 25	-$17M	-$17M
Q2 25	-$16M	-$16M
Q3 25	-$15M	-$15M
Q4 25	-$2M	-$2M

Capital Expenditures

Quarter	CapEx
Q1 22	$47.0K
Q2 22	$266.0K
Q3 22	$224.0K
Q4 22	$54.0K
Q1 23	$35.0K
Q2 23	$27.0K
Q3 23	$19.0K
Q4 23	$3.0K
Q1 24	$8.0K
Q2 24	$107.0K
Q3 24	$68.0K
Q4 24	$106.0K
Q1 25	$112.0K
Q2 25	$34.0K
Q3 25	$310.0K
Q4 25	$33.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	-34.2%	+14.5%
Q2 22	+141.0%	+74.4%
Q3 22	-12.8%	+96.3%
Q4 22	+145.0%	+100.4%
Q1 23	+34.4%	+112.0%
Q2 23	+128.2%	+72.6%
Q3 23	-64.0%	+33.1%
Q4 23	-76.2%	+16.6%
Q1 24	-46.7%	+18.4%
Q2 24	-15.0%	+27.2%
Q3 24	+135.6%	+16.0%
Q4 24	-3.4%	+32.9%
Q1 25	+40.0%	+31.5%
Q2 25	+7.5%	+14.3%
Q3 25	-12.8%	+22.2%
Q4 25	+12120.2%	+42.7%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$70.0K	8.1%
Q2 22	$0	0.0%
Q3 22	$0	0.0%
Q4 22	$863.0K	78.2%
Q1 23	$0	0.0%
Q2 23	$0	0.0%
Q3 23	$4M	837.7%
Q4 23	$919.0K	350.8%
Q1 24	$3M	417.4%
Q2 24	$3M	354.9%
Q3 24	$2M	239.5%
Q4 24	$3M	1147.0%
Q1 25	$3M	341.6%
Q2 25	$3M	388.8%
Q3 25	$3M	349.9%
Q4 25	$3M	8.9%

OpEx Breakdown

Quarter	R&D	SG&A
Q1 22	$3M	$2M
Q2 22	$5M	$3M
Q3 22	$6M	$5M
Q4 22	$8M	$3M
Q1 23	$8M	$4M
Q2 23	$8M	$5M
Q3 23	$9M	$6M
Q4 23	$9M	$4M
Q1 24	$9M	$6M
Q2 24	$11M	$6M
Q3 24	$12M	$6M
Q4 24	$11M	$6M
Q1 25	$13M	$6M
Q2 25	$14M	$6M
Q3 25	$14M	$7M
Q4 25	$17M	$7M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$29M	$738.0K	$30M
Q2 22	$107M	$579.0K	$108M
Q3 22	$97M	$251.0K	$97M
Q4 22	$20M	$64M	$84M
Q1 23	$19M	$109M	$127M
Q2 23	$16M	$101M	$118M
Q3 23	$19M	$90M	$109M
Q4 23	$31M	$57M	$88M
Q1 24	$23M	$52M	$75M
Q2 24	$24M	$41M	$65M
Q3 24	$26M	$41M	$67M
Q4 24	$22M	$45M	$67M
Q1 25	$18M	$32M	$50M
Q2 25	$19M	$15M	$34M
Q3 25	$42M	$54M	$96M
Q4 25	$35M	$72M	$107M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	32M	+54.6%	+54.6%
Q2 22	32M	0.0%	+54.6%
Q3 22	23M	-26.3%	+13.9%
Q4 22	23M	0.0%	+13.9%
Q1 23	28M	+18.6%	-12.6%
Q2 23	35M	+25.2%	+9.5%
Q3 23	35M	+1.8%	+51.3%
Q4 23	36M	+1.5%	+53.5%
Q1 24	36M	+0.0%	+29.4%
Q2 24	36M	+0.1%	+3.4%
Q3 24	38M	+5.1%	+6.7%
Q4 24	38M	+1.2%	+6.4%
Q1 25	38M	+0.4%	+6.9%
Q2 25	38M	+0.4%	+7.2%
Q3 25	38M	0.0%	+2.0%
Q4 25	38M	0.0%	+0.9%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	—	—
Q2 22	—	—
Q3 22	—	—
Q4 22	—	—
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	$4.7K	56
Q1 24	$11.1K	56
Q2 24	$13.9K	56
Q3 24	$17.6K	56
Q4 24	$3.6K	70
Q1 25	$12.4K	70
Q2 25	$11.9K	70
Q3 25	$12.3K	70
Q4 25	$359.5K	86

Revenue / Employee